---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-069176"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:32:09.753911+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Karyopharm Reports Q1 2025 Revenue of $30.0M, Net Loss of $23.5M; Phase 3 SENTRY Trial Passes Futility Analysis

## Summary
- Total revenue $30.0M; U.S. XPOVIO net product revenue $21.1M, impacted by $5.0M increase in product return reserve for expired 80 mg and 100 mg units.
- Phase 3 SENTRY trial (selinexor + ruxolitinib) passed futility analysis, is ~80% enrolled; target enrollment expected June/July 2025.
- Phase 2 XPORT-MF-035 data: selinexor monotherapy achieved SVR25 in 67% of evaluable patients vs 38% with physician's choice.
- Reaffirms full-year 2025 guidance: total revenue $140M–$155M, U.S. XPOVIO net product revenue $115M–$130M.
- Cash, cash equivalents and investments $70.3M as of March 31, 2025; exploring alternatives to extend cash runway.

## SEC filing metadata
- accession: 0000950170-25-069176
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000095017025069176/0000950170-25-069176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000095017025069176/kpti-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-069176
- JSON: https://secwatch.observer/filing/0000950170-25-069176.json
- Plain text: https://secwatch.observer/filing/0000950170-25-069176.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.